Agamree is a medicine for treating Duchenne muscular dystrophy in patients from 4 years of age. Duchenne muscular dystrophy is a genetic disease that gradually causes weakness and loss of muscle function. Duchenne muscular dystrophy is rare, and Agamree was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 22 August 2014. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1309). Agamree contains the active substance vamorolone.
Therapeutic Indication
### Therapeutic indication Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.
Therapeutic Area (MeSH)
ATC Code
H02AB18
ATC Item
vamorolone
Pharmacotherapeutic Group
Glucocorticoids
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Vamorolone | N/A | Vamorolone |
| vamorolone | N/A | Vamorolone |
EMA Name
Agamree
Medicine Name
Agamree
Aliases
N/ANo risk management plan link.
